Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19187027 | 0.84 | CRBN (0.43) | PKMCRBNGPR84ALDH1A1CYP2C19 | |
| SCHEMBL24023212 | 0.83 | PKM (0.42) | PKMCRBNGPR84ALDH1A1CYP2C19 | |
| SCHEMBL17394619 | 0.81 | PKM (0.41) | PKMCRBNGPR84ALDH1A1CYP2C19 | |
| SCHEMBL22327126 | 0.78 | GPR84 (0.44) | PKMCRBNGPR84ALDH1A1CYP2C19 | |
| SCHEMBL18479912 | 0.78 | GPR84 (0.44) | PKMCRBNGPR84ALDH1A1CYP2C19 | |
| SCHEMBL10598535 | 0.78 | PKM (0.38) | PKMCRBNALDH1A1CYP2C19DUT | |
| SCHEMBL16289906 | 0.77 | CRBN (0.40) | PKMCRBNALDH1A1DDB1DUT | |
| SCHEMBL23621035 | 0.77 | ALDH1A1 (0.54) | PKMCRBNGPR84ALDH1A1CYP2C19 | |
| SCHEMBL19612731 | 0.77 | PKM (0.38) | PKMCRBNGPR84ALDH1A1CYP2C19 | |
| SCHEMBL23620741 | 0.76 | GPR84 (0.42) | PKMCRBNGPR84ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582748-B2 | efficient synthetic route to an optionally protected 1-halo-2-deoxyribose; formation of an alkyl acetal, such as a methyl acetal, of a furanose, such as 2-deoxyribose, optionally protecting the remaining hydroxyl groups of the furanose, reacting the acetal with an acyl halide that forms the acid halide | MICROBIOLOGICA QUIMICA E FARMACEUTICAL LTD. (BR) | 2009-09-01 | — | — | US | disclosed |
| EP-1745573-A2 | METHODS OF MANUFACTURE OF 2 -DEOXY-&bgr;-L-NUCLEOSIDES | Microbiologica Quimica E Farmaceutica Ltd. (BR) | 2007-01-24 | — | — | EP | disclosed |
| US-20040266996-A1 | Methods of manufacture of 2'-deoxy-beta-L-nucleosides | MICROBIOLOGICA QUIMICA E FARMACEUTICA LTD. (BR) | 2004-12-30 | — | — | US | disclosed |
| WO-2004084453-A2 | METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES | MICROBIOLOGICA QUIMICA E FARMACEUTICA LTD. (BR) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266996-A1 | Methods of manufacture of 2'-deoxy-beta-L-nucleosides | DUT, DAO, DCTD | PKM 3017/4885CRBN 4719/4885GPR84 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.